ENTONASDAQHealthcare · Biotechnology

Entero Therapeutics, Inc.

$2.85-5.00%($-0.15)

TickerSpark Score

43/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENTO research report →

52-Week Range39% of range

Low $0.97

Current $2.85

High $5.84

Companywww.firstwavebio.com

First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease.

CEO: Jason David Sawyer
IPO: 2016
Employees: 2
HQ: Boca Raton, FL, US

Price Chart

+90.00% · this period

Valuation

Market Cap: $13.58M
P/E: -0.95
P/S: 358.90
P/B: 0.26
EV/EBITDA: -2.17
Div Yield: 0.00%

Profitability

Gross Margin: -3398.93%
Op Margin: -19539.98%
Net Margin: -18078.34%
ROE: -11.92%
ROIC: -18.21%

Growth & Income

Revenue: $36.25K · 0.00%
Net Income: $-6,553,578 · 63.71%
EPS: $-4.16 · -7.22%
Op Income: $-7,083,438
FCF YoY: 38.13%

Performance & Tape

52W High: $5.84
52W Low: $0.97
50D MA: $4.07
200D MA: $2.24
Beta: 1.19
Avg Volume: 216.27K

Get TickerSpark's AI analysis on ENTO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime